       AdvisorsClinical
Scientific
Clinical Advisors
Robert C. Moellering Jr., M.D. Chair of Rib-X Clinical Advisory Board, Professor Harvard Medical School
Dr. Robert Moellering is the Shields Warren-Mallinckrodt Professor of Medical Research at Harvard Medical School. His previous experience includes serving as Physician-in-Chief at the New England Deaconess Hospital, Herrman L. Blumgart Professor of Medicine at Harvard Medical School, Physician-in-Chief and Chairman of the Department of Medicine at the Beth Israel Deaconess Medical Center (BIDMC) in Boston and President and C.E.O. of Harvard Medical Faculty Physicians at BIDMC. Trained as an infectious diseases specialist, Dr. Moellering has been actively involved in laboratory research for the past 35 years carrying out numerous studies of the mechanisms of action and mechanisms of resistance to antimicrobial agents and his work is reported in over 400 publications in scientific journals. He is a Fellow of the Infectious Diseases Society of America, Master of the American College of Physicians, an Honorary Fellow of the Royal College of Physicians, and has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians. He is Editor-in-Chief Emeritus of Antimicrobial Agents and Chemotherapy, Editor of Infectious Disease Clinics of North America and Associate Editor of the Journal of Infection and Public Health. Dr. Moellering has received many prestigious awards, including an honorary Doctor of Science degree from Valparaiso University, the Garrod Medal from the British Society for Antimicrobial Chemotherapy, the Feldman Award and the Maxwell Finland Award from the Infectious Diseases Society of America, the Hoechst-Roussel Award from the American Academy for Microbiology and, in 2006, the Maxwell Finland Award for Scientific Achievement from the National Foundation for Infectious Diseases. Most recently, he is the 2008 recipient of the Alexander Fleming Award for Lifetime Achievement from the Infectious Diseases Society of America.
New England Medical Center, Tufts University
Dr. Helen Boucher is Assistant Professor of Medicine, Program Director of the Infectious Diseases Fellowship and Staff Physician in the Division of Geographic Medicine and Infectious Diseases at Tufts University New England Medical Center in Boston, Massachusetts. Dr. Boucher is board certified in internal medicine and Infectious diseases. Her clinical interests include infections in immunocompromised patients with an emphasis on transplant-related bacterial and fungal infections and human immunodeficiency virus as well as Staphylococcus aureus infections. Her research interests focus on S. aureus and the development of new anti-infective agents. She is the author or coauthor of numerous abstracts, chapters and peer-reviewed articles, which have been published in such journals as The New England Journal of Medicine, Antimicrobial Agents and Chemotherapy, Clinical Infectious Diseases, and Drugs. Dr. Boucher is a member of several professional organizations, among them the Infectious Diseases Society of America, the American Society for Microbiology and the American Medical Association. In 1998, the Massachusetts Infectious Diseases Society awarded Dr. Boucher the Edward H. Kass Award for Clinical Excellence. In May, 2006, she was elected to the Antimicrobial Availability Task Force (AATF) of the Infectious Diseases Society of America (IDSA) and in October, 2007, she was elected to the Research Committee of the IDSA. Dr. Boucher received her medical degree from the University of Texas Medical School at Houston. She completed her internship, residency and chief residency in Internal Medicine at the New England Deaconess Hospital and her clinical and research fellowships in Infectious Diseases at the Beth Israel Deaconess Medical Center.
University of California, San Francisco
Dr. Henry Chambers is Professor of Medicine, Chief, Division of Infectious Diseases, San Francisco General Hospital and Director of the University of California, San Francisco Infectious Diseases Fellowship Training Program. Dr. Chambers' research interests include antimicrobial resistance, the genetics, molecular basis and epidemiology of methicillin resistant Staphylococcus aureus, staphylococcal infections and tuberculosis. Dr. Chambers received his M.D. from Vanderbilt University in Nashville, Tennessee. He completed his residency and Chief Residency in Internal Medicine at San Francisco General Hospital/University of California, San Francisco and completed fellowships in both General Medicine and Infectious Disease at the same institution.
University of Texas Medical School
Dr. Barbara E. Murray is Director, Division of Infectious Diseases and J. Ralph Meadows Professor at the University of Texas – Houston Medical School and co-director of the UTHSC-H Center for the Study of Emerging and Re-Emerging Pathogens. Her previous experience includes conducting research at the Armed Forces Research Institute of Medical Sciences in Thailand; serving as Assistant Professor and Professor at the University of Texas-Houston Medical School. Dr. Murray's broad research interests involve the genetic and biochemical mechanisms of resistance to antibiotics and bacterial pathogenicity, particularly relating to enterococci, and molecular epidemiologic typing methods. Dr. Murray is a nationally and internationally recognized expert in infectious diseases, microbiology and bacterial pathogenesis, conducts N.I.H. funded research (including a current MERIT award), has served on a number of N.I.H. committees and study sections, including as past Chair of the N.I.H. Recombinant DNA Advisory Committee, as well as on the F.D.A.'s Anti-Infectives Advisory Committee. She has also served on a number of Advisory Boards as a consultant to the pharmaceutical industry. She is past chair (3 year term) of the Program Planning Committee of the American Society of Microbiology's ICAAC meeting, the world’s largest infectious diseases meeting. She served a 10-year term as an editor of Antimicrobial Agents and Chemotherapy, a journal published by the American Society of Microbiology and currently serves on the Program Committee of the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Dr. Murray is a frequent visiting professor at other medical schools and a frequent invited speaker at national and international meetings. Dr. Murray is an active member of the Infectious Diseases Society of America and is its Secretary-Treasurer. Dr. Murray received her B.A. cum laude in mathematics from Rice University, and received her M.D., graduating first in her class (Ho Din Award and AOA) from the University of Texas Medical School. She then spent six years training in Internal Medicine and Infectious Diseases at Harvard Medical School's Massachusetts General Hospital, in Boston.
Scientific Advisors
Co-Founder and Chair of Scientific Advisory Board
Dr. Thomas Steitz is the Sterling Professor of Molecular Biophysics and Biochemistry and a Howard Hughes Medical Institute Investigator at Yale University. He was elected to the National Academy of Sciences in 1990. His research in the field of protein and nucleic acid X-ray crystallography, including his recent work with Prof. Moore on the 50S ribosome structure, has had wide-ranging impact in the global scientific community. In 2001, Prof. Steitz together with Prof. Moore and Prof. Noller received the Rosenstiel Award for Distinguished Work in Basic Medical Sciences for their research on the ribosome. Together with Professor Venki Ramakrishnan of the MRC and Professor Ada Yonath of the Weitzmann Institute, Professor Steitz was awarded the Nobel Prize in Chemistry in 2009 for studies of the structure and function of the ribosome.
Co-Founder
Dr. John Abelson is the George Beadle Emeritus Professor of Biology at the California Institute of Technology. He was elected to the National Academy of Sciences in 1985. His focus on the chemistry and molecular biology of RNA structure and function contributes to Rib-X’s fundamental understanding of very basic biological processes. He is a Co-Founder and member of the Board of Directors of the Agouron Institute.
Co-Founder
Dr. William Jorgensen is the Sterling Professor of Chemistry at Yale University. He was elected to the National Academy of Sciences in 2011. His work in the area of computational methods for drug design is applied widely in both academic and pharmaceutical research and he has received a number of American Chemical Society awards recognizing his accomplishments.
Co-Founder
Dr. Moore is the Sterling Professor of Chemistry at Yale University. He was elected to the National Academy of Sciences in 1997. His career research focus in the area of biophysical chemistry and the structure and function of macromolecular assemblies has produced an invaluable understanding of RNA-ribosome structure and function for both the academic and pharmaceutical community. In 2001, Prof. Moore, together with Professors Steitz and Noller, received the Rosenstiel Award for Distinguished Work in Basic Medical Sciences for their research on the ribosome.
Co-Founder
Dr. Harry Noller is the Robert Louis Sinsheimer Professor of Molecular Biology at the University of California, Santa Cruz. He was elected to the National Academy of Sciences in 1992. He is an invaluable addition to the Scientific Board because of his long-term research on ribosomal RNA structure and function. In 2001, Prof. Noller, together with Professors Moore and Steitz, received the Rosenstiel Award for Distinguished Work in Basic Medical Sciences for their research on the ribosome. Prof. Noller is also co-recipient of the 2007 Paul Ehrlich and Ludwig Darmstaedter Prize awarded by the Paul Ehrlich Foundation.
Venkatraman Ramakrishnan, Ph.D. Medical Research Council
Dr. Venkatraman Ramakrishnan is Group Leader at the Medical Research Council Laboratory of Molecular Biology in Cambridge, England. He was elected to the European Molecular Biology Organization in 2002. His research on the structure of the ribosome has helped elucidate the structural basis for the accuracy of protein synthesis as well as the action of antibiotics that target the small ribosomal subunit. For this work, he was elected Fellow of the Royal Society in 2003. Together with Professor Tom Steitz of Yale University and Professor Ada Yonath of the Weitzmann Institute, Professor Ramakrishnan was awarded the Nobel Prize in Chemistry in 2009 for studies of the structure and function of the ribosome.
|
